Life Sciences Partner Quoted in Bloomberg BNA’s Health Care Daily Report on Drug Industry Facing Less Scrutiny Under President Trump and the New U.S. Congress

In The News
November 15, 2016

Life sciences partner Greg Levine (Washington, D.C.) was quoted in a Nov. 10 Bloomberg BNA Health Care Daily Report article on the drug industry possibly facing less scrutiny under President-elect Donald Trump and the new U.S. Congress.

Mr. Levine expects staff turnover in key leadership positions at the U.S. Food and Drug Administration along with expedited drug approvals and reduced regulatory burdens for the life sciences industry. A more conservative U.S. Supreme Court is likely to continue the trend of extending First Amendment protections to commercial speech including manufacturers’ ability to disseminate information about unapproved or off-label uses of products. However, Trump’s tough stance on trade issues with China and other countries could also have negative repercussions for the drug industry.